Celecoxib Plus Aspirin Versus Naproxen and Lansoprazole Plus Aspirin: A Randomized, Double-Blind, Endoscopic Trial

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 10, 2007, Pages 1167-1174

  Goldstein, Jay L ^a   Cryer, Byron ^b   Amer, Fouad ^c   Hunt, Barbara ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATTAPULGITE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOODY DIARRHEA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOSCOPY; ERUCTATION; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEART PALPITATION; HELICOBACTER INFECTION; HEMORRHAGIC COLITIS; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PROTON PUMPS; PYRAZOLES; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH ULCER; SULFONAMIDES; UNITED STATES;

EID: 34748839233     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.06.009     Document Type: Article

References (41)

1. Ansani NT, Fedutes BA, Vogt M, et al. Rheumatologic medication utilization in 2003: prescribing trends and retail sales costs. Poster presented at Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals; October 18, 2004; San Antonio, TX. A correction was published at http://www.rheumatology.org/press/2004/fedutes_nsaid.asp.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
3. Bjorkman D.J. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 107 Suppl 6A (1999) S3-S8
4. Ofman J.J., MacLean C.H., Straus W.L., et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol 29 (2002) 804-812
5. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002) 169-175
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [published correction appears in BMJ 2002;324:141]. BMJ 324 (2002) 71-86
7. Rodondi N., Vittinghoff E., Cornuz J., et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med 118 (2005) 1288
8. Paulose-Ram R., Hirsch R., Dillon C., et al. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults. Pharmacoepidemiol Drug Saf 14 (2005) 257-266
9. Brown J.B., Delea T.E., Nichols G.A., et al. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med 162 (2002) 193-199
10. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
11. Garcia Rodriguez L.A., Hernandez-Diaz S., and de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 562-571
12. Goldstein J.L., Huang B., Amer F., et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post hoc subanalysis. Clin Ther 26 (2004) 1637-1643
13. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
14. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial-Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
15. Goldstein J.L., Lowry S.C., Lanza F.L., et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 23 (2006) 1489-1498
16. Hawkey C., Laine L., Simon T., et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial-the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43 (2000) 370-377
17. Laine L., Harper S., Simon T., et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis: Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117; (1999) 776-783
18. Goldstein J.L., Eisen G.M., Agrawal N., et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 20 (2004) 527-538
19. Rordorf C., Kellett N., Mair S., et al. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18 (2003) 533-541
20. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
21. Laine L., Maller E.S., Yu C., et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127 (2004) 395-402
22. Cox E.R., Frisse M., Behm A., et al. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 164 (2004) 1243-1246
23. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
24. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
25. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
26. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
27. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
28. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary?. Rev Gastroenterol Disord 4 Suppl 4 (2004) S33-S41
29. Chan F.K., and Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther 19 (2004) 1051-1061
30. Fendrick A.M., and Garabedian-Ruffalo S.M. A clinician's guide to the selection of NSAID therapy. Pharmacy and Therapeutics 27 (2002) 579-582
31. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update-American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 (2000) 1905-1915
32. Goldstein J.L. Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion 69 Suppl 1 (2004) 25-33
33. Patrono C., Garcia Rodriguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
34. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354 (1999) 2106-2111
35. Goldstein J.L., Correa P., Zhao W.W., et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96 (2001) 1019-1027
36. Goldstein J.L., Aisenberg J., Berger M., et al. Effects of concomitant aspirin (81 mg qd) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized, placebo-controlled trial. (abstract). Gastroenterology 130 Suppl 2 (2006) A-81
37. Goldstein J.L., Agrawal N.M., Silverstein F., et al. Influence of H pylori (Hp) infection and/or low dose aspirin (ASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs. (abstract). Gastroenterology 116 (1999) A174
38. Goldstein J.L., Kent J., Shu V., et al. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease. Gastroenterology 122 Suppl 1 (2002) A345 (abstract)
39. Cullen D., Bardhan K.D., Eisner M., et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12 (1998) 135-140
40. Ekstrom P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 31 (1996) 753-758
41. Laine L., Curtis S.P., Cryer B., et al. Upper gastrointestinal clinical events and symptoms in the double-blind multinational etoricoxib and diclofenac arthritis long-term (MEDAL) program. Lancet 369 (2007) 465-473